vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and MEDICAL PROPERTIES TRUST INC (MPW). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $270.3M, roughly 1.0× MEDICAL PROPERTIES TRUST INC). MEDICAL PROPERTIES TRUST INC runs the higher net margin — 6.5% vs -45.7%, a 52.2% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 16.6%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -0.2%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Medical Properties Trust, Inc. (MPT) is an international real estate investment trust (REIT) based in Birmingham, Alabama that purchases and invests in healthcare facilities and for-profit healthcare holding companies, primarily in the United States and Europe. Their property acquisitions often come in the form of sale-leaseback agreements, in which the original property owner sells the property to MPT and becomes their tenant. MPT's tenants are generally subject to long-term triple net lease...
GH vs MPW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $270.3M |
| Net Profit | $-128.5M | $17.6M |
| Gross Margin | 64.6% | 95.8% |
| Operating Margin | -43.0% | 9.7% |
| Net Margin | -45.7% | 6.5% |
| Revenue YoY | 39.4% | 16.6% |
| Net Profit YoY | -15.8% | 104.3% |
| EPS (diluted) | $-1.01 | $0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $270.3M | ||
| Q3 25 | $265.2M | $237.5M | ||
| Q2 25 | $232.1M | $240.4M | ||
| Q1 25 | $203.5M | $223.8M | ||
| Q4 24 | $201.8M | $231.8M | ||
| Q3 24 | $191.5M | $225.8M | ||
| Q2 24 | $177.2M | $266.6M | ||
| Q1 24 | $168.5M | $271.3M |
| Q4 25 | $-128.5M | $17.6M | ||
| Q3 25 | $-92.7M | $-77.7M | ||
| Q2 25 | $-99.9M | $-98.4M | ||
| Q1 25 | $-95.2M | $-118.3M | ||
| Q4 24 | $-111.0M | $-412.3M | ||
| Q3 24 | $-107.8M | $-801.2M | ||
| Q2 24 | $-102.6M | $-320.6M | ||
| Q1 24 | $-115.0M | $-875.6M |
| Q4 25 | 64.6% | 95.8% | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | 91.8% | ||
| Q1 25 | 63.3% | 63.6% | ||
| Q4 24 | 61.6% | 90.9% | ||
| Q3 24 | 61.1% | 96.5% | ||
| Q2 24 | 59.1% | 98.4% | ||
| Q1 24 | 61.2% | 84.9% |
| Q4 25 | -43.0% | 9.7% | ||
| Q3 25 | -37.3% | -28.0% | ||
| Q2 25 | -45.9% | -36.7% | ||
| Q1 25 | -54.6% | -48.5% | ||
| Q4 24 | -62.4% | -173.7% | ||
| Q3 24 | -61.3% | -350.7% | ||
| Q2 24 | -56.8% | -114.5% | ||
| Q1 24 | -59.2% | -318.6% |
| Q4 25 | -45.7% | 6.5% | ||
| Q3 25 | -35.0% | -32.7% | ||
| Q2 25 | -43.0% | -40.9% | ||
| Q1 25 | -46.8% | -52.8% | ||
| Q4 24 | -55.0% | -177.8% | ||
| Q3 24 | -56.3% | -354.8% | ||
| Q2 24 | -57.9% | -120.3% | ||
| Q1 24 | -68.2% | -322.7% |
| Q4 25 | $-1.01 | $0.03 | ||
| Q3 25 | $-0.74 | $-0.13 | ||
| Q2 25 | $-0.80 | $-0.16 | ||
| Q1 25 | $-0.77 | $-0.20 | ||
| Q4 24 | $-0.90 | $-0.68 | ||
| Q3 24 | $-0.88 | $-1.34 | ||
| Q2 24 | $-0.84 | $-0.54 | ||
| Q1 24 | $-0.94 | $-1.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $540.9M |
| Total DebtLower is stronger | $1.5B | $9.7B |
| Stockholders' EquityBook value | $-99.3M | $4.6B |
| Total Assets | $2.0B | $15.0B |
| Debt / EquityLower = less leverage | — | 2.11× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $540.9M | ||
| Q3 25 | $580.0M | $396.6M | ||
| Q2 25 | $629.1M | $509.8M | ||
| Q1 25 | $698.6M | $673.5M | ||
| Q4 24 | $525.5M | $332.3M | ||
| Q3 24 | $585.0M | $275.6M | ||
| Q2 24 | $933.7M | $606.5M | ||
| Q1 24 | $1.0B | $224.3M |
| Q4 25 | $1.5B | $9.7B | ||
| Q3 25 | $1.1B | $9.6B | ||
| Q2 25 | $1.1B | $9.6B | ||
| Q1 25 | $1.1B | $9.5B | ||
| Q4 24 | $1.1B | $8.8B | ||
| Q3 24 | — | $9.2B | ||
| Q2 24 | — | $9.4B | ||
| Q1 24 | — | $10.1B |
| Q4 25 | $-99.3M | $4.6B | ||
| Q3 25 | $-354.5M | $4.7B | ||
| Q2 25 | $-305.5M | $4.8B | ||
| Q1 25 | $-250.8M | $4.8B | ||
| Q4 24 | $-139.6M | $4.8B | ||
| Q3 24 | $-60.1M | $5.4B | ||
| Q2 24 | $-1.6M | $6.2B | ||
| Q1 24 | $68.3M | $6.7B |
| Q4 25 | $2.0B | $15.0B | ||
| Q3 25 | $1.3B | $14.9B | ||
| Q2 25 | $1.3B | $15.2B | ||
| Q1 25 | $1.3B | $14.9B | ||
| Q4 24 | $1.5B | $14.3B | ||
| Q3 24 | $1.5B | $15.2B | ||
| Q2 24 | $1.6B | $16.2B | ||
| Q1 24 | $1.7B | $17.3B |
| Q4 25 | — | 2.11× | ||
| Q3 25 | — | 2.06× | ||
| Q2 25 | — | 2.00× | ||
| Q1 25 | — | 1.99× | ||
| Q4 24 | — | 1.83× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | 1.51× | ||
| Q1 24 | — | 1.51× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $230.8M |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | 13.11× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $230.8M | ||
| Q3 25 | $-35.4M | $18.6M | ||
| Q2 25 | $-60.3M | $51.7M | ||
| Q1 25 | $-62.7M | $384.0K | ||
| Q4 24 | $-64.5M | $245.5M | ||
| Q3 24 | $-51.1M | $59.2M | ||
| Q2 24 | $-94.0M | $35.3M | ||
| Q1 24 | $-30.3M | $74.3M |
| Q4 25 | $-54.2M | — | ||
| Q3 25 | $-45.8M | — | ||
| Q2 25 | $-65.9M | — | ||
| Q1 25 | $-67.1M | — | ||
| Q4 24 | $-83.4M | — | ||
| Q3 24 | $-55.3M | — | ||
| Q2 24 | $-99.1M | — | ||
| Q1 24 | $-37.2M | — |
| Q4 25 | -19.3% | — | ||
| Q3 25 | -17.3% | — | ||
| Q2 25 | -28.4% | — | ||
| Q1 25 | -33.0% | — | ||
| Q4 24 | -41.3% | — | ||
| Q3 24 | -28.9% | — | ||
| Q2 24 | -55.9% | — | ||
| Q1 24 | -22.1% | — |
| Q4 25 | 9.9% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 9.4% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 2.9% | — | ||
| Q1 24 | 4.1% | — |
| Q4 25 | — | 13.11× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
MPW
Segment breakdown not available.
